Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

Figure S5 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

<p>Supplemental Figure 5: Combination therapy of XVir-N-31 and CDK4/6 inhibitor LEE011 induces calreticulin (CALR) surface expression and increases phagocytosis in vitro.</p>

Spremljeno u:

Bibliografski detalji
Glavni autor:	Sebastian Johannes Schober (14971891) (author)
Daljnji autori:	Caroline Schoening (14971894) (author), Jennifer Eck (14971897) (author), Charlotte Middendorf (14971900) (author), Julia Lutsch (14971903) (author), Pia Knoch (14971906) (author), Anna Josefine von Ofen (14971909) (author), Hendrik Gassmann (14971912) (author), Melanie Thiede (14971915) (author), Julia Hauer (14971918) (author), Andreas Kolk (14971921) (author), Klaus Mantwill (14971924) (author), Jürgen E. Gschwend (14971927) (author), Stefan E.G. Burdach (14971930) (author), Roman Nawroth (14971933) (author), Uwe Thiel (14971936) (author), Per Sonne Holm (14971939) (author)
Izdano:	2025
Teme:	Cancer Therapeutic Research and Development Immuno-oncology Immunotherapy Combination immunotherapy Pediatric Cancers Sarcomas Translational Research
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti

Figure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
od: Sebastian Johannes Schober (14971891)
Izdano: (2025)

Figure S2 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
od: Sebastian Johannes Schober (14971891)
Izdano: (2025)

Figure S3 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
od: Sebastian Johannes Schober (14971891)
Izdano: (2025)

Figure S4 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma
od: Sebastian Johannes Schober (14971891)
Izdano: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
od: Kankan Cao (16437263)
Izdano: (2025)

Figure S1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Izdano: (2025)

Figure S2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Izdano: (2025)

Figure S3 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Izdano: (2025)

Figure S4 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Izdano: (2025)

Figure S5 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Izdano: (2025)

Figure S6 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Izdano: (2025)

Figure S7 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Izdano: (2025)

Supplementary Table 1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Izdano: (2025)

Supplementary Table 2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Izdano: (2025)

Supplementary Fig. S1 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer
od: Sahar Mafi (16721657)
Izdano: (2025)

Supplementary Fig. S2 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer
od: Sahar Mafi (16721657)
Izdano: (2025)

Figure S1 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S3 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S5 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
od: Jian Wang (15048011)
Izdano: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
od: Daniel S. Green (15047598)
Izdano: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Izdano: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Izdano: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Izdano: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
od: Caroline Robert (15032672)
Izdano: (2025)

Diversity of augmented graphs.
od: Hossein Rafieizadeh (22676722)
Izdano: (2025)

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
od: Jitske van den Bulk (17142147)
Izdano: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
od: Jitske van den Bulk (17142147)
Izdano: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
od: Jitske van den Bulk (17142147)
Izdano: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
od: Jitske van den Bulk (17142147)
Izdano: (2025)

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma
od: Jitske van den Bulk (17142147)
Izdano: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
od: Arianna Draghi (15126339)
Izdano: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
od: Arianna Draghi (15126339)
Izdano: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
od: Arianna Draghi (15126339)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_v9kcjipvc9d2rrqosf89ilr6a7